# An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Study · id `cardio:ct-nct03354273` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03354273](<https://clinicaltrials.gov/study/NCT03354273>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03354273

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 730 participants.

## Technical summary

Registry record NCT03354273. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-06-05 (actual); primary completion 2022-05-05 (actual). Results posted on 2023-07-12.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 730 participants (enrolled count; ClinicalTrials.gov record NCT03354273, source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)
- Started: 2018-06-05 (actual) (ClinicalTrials.gov record NCT03354273, source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)
- Primary completion: 2022-05-05 (actual) (ClinicalTrials.gov record NCT03354273, source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)
- Completion: 2022-05-05 (actual) (ClinicalTrials.gov record NCT03354273, source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)
- Results first posted: 2023-07-12 (ClinicalTrials.gov record NCT03354273, source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)
- Countries: United States; Canada; Finland; France; Germany; Netherlands; Switzerland (ClinicalTrials.gov record NCT03354273, source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03354273-2023-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
- Condition: Coronary Artery Disease (CAD)
- Intervention (Drug): PET MPI
- Intervention (Drug): SPECT MPI
- Intervention (Drug): Pharmacological stress agents
- Lead sponsor: GE Healthcare
- Lead sponsor class: INDUSTRY
- Collaborator: Pharmaceutical Product Development, (PPD) LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: GE Healthcare (`cardio:org-ge-healthcare`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease (`cardio:pubmed-37821170`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Improved assessment of coronary artery disease in obese patients with flurpiridaz-18F positron emission tomography myocardial perfusion imaging: A prespecified subgroup analysis of the AURORA phase 3 study (`cardio:pubmed-42128226`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: da0d9a0cd3549d504a4f8b12f03f4241d695fe84890c9d0a923f286f59fed660
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
